SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Send an e-mail with your comments!
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
TODAY'S NEWS
New Ebola vaccine hope
Thurs November 27th - An Ebola vaccine has shown promise in tests on volunteers, US researchers announced last night. More
Rheumatic heart disease neglected
Thurs November 27th - Heart disease triggered by rheumatic fever is being widely neglected by health care services worldwide, a new report warns. More
Liver disease rethink call
Thurs November 27th - The UK needs a radical new approach to liver disease to prevent the NHS being overwhelmed by growing numbers of patients, experts say today. More
RECENT COMMENTS
On 12/09/2014 Barry Stanley wrote:
The references in this publication did not include... on Effects of binge drinking in p...
On 12/09/2014 Barry Stanley wrote:
The references in this publication did not include... on Effects of binge drinking in p...
On 05/07/2014 paul wrote:
have i got this wrong? Sir simon came out in 201... on Veteran trauma overstated, say...
On 26/06/2014 monica sawitz wrote:
I am a retired RGN, went to GP on 19/5/14, gave me... on Questions over whooping cough ...
On 30/07/2013 chrisdbr wrote:
does this mean that Collagen supplements might be ... on Protein hope for osteoarthriti...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Benefits of early HIV treatment

Thursday January 17th, 2013

Sustained treatment of HIV infection early on in the disease can have long term benefits for patients, researchers reported last night.

The British led study tested the benefits of treating patients with anti-viral drugs for 48 weeks as early as possible in the course of infection.

Research was undertaken in countries such as Australia, South Africa, Brazil, Spain, Italy and Ireland.

It involved some 366 adults over five years.

Reporting in the New England Journal of Medicine, the researchers say the treatment reduced viral levels in the blood for up to 60 weeks after treatment was stopped.

It also delayed the need for long-term treatment - although the delay was only a little longer than the 48 weeks that patients had already spent on drugs.

Researcher Dr Sarah Fidler, from Imperial College London, said: "These results are promising and suggest that a year-long course of treatment for people recently infected with HIV may have some benefit on both the immune system as well as helping control the virus.

"The treatment also reduces the amount of virus in the body for some time after the patient has stopped taking the medication. This could be very important for helping reduce the risk of passing on the virus to a sexual partner."

Professor Gita Ramjee, director of the South African Medical Research Council's HIV Prevention Research Unit, said: "We now need to weigh up whether the benefits offered by early intervention are outweighed by the strategic and financial challenges such a change in policy would incur, particularly in resource-poor settings such as Africa, although this may be where the most benefits are seen in terms of TB rates."

SPARTAC Trial Investigators. The effect of short-course antiretroviral therapy in primary HIV infection: final results from SPARTAC, an international randomized controlled trial. NEJM; 17 Jan 2013.

Tags: Africa | Europe | Flu & Viruses | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES